This is an obsolete version of the rule. Please click on the rule number to view the current version.


(1) The following communicable diseases and conditions are reportable:

(a) AIDS, as defined by the Centers for Disease Control and Prevention, and HIV infection, as determined by a positive result from a test approved by the Federal Food and Drug Administration for the detection of HIV, including, but not limited to, antibody, antigen, and all HIV nucleic acid tests;

(b) Anaplasmosis;

(c) Anthrax;

(d) Arboviral Disease (California serogroup, Eastern equine encephalitis, Powassan, Saint Louis encephalitis, West Nile Virus, Western equine encephalitis);

(e) Babesiosis;

(f) Botulism (including infant botulism);

(g) Brucellosis;

(h) Campylobacter;

(i) Chancroid;

(j) Chlamydial trachomatis infection;

(k) Cholera;

(l) Coccidioidomycosis;

(m) Colorado tick fever;

(n) Cryptosporidiosis;

(o) Cyclosporiasis;

(p) Dengue virus infections;

(q) Diphtheria;

(r) Erlichiosis;

(s) Escherichia coli, shiga toxin-producing (STEC);

(t) Gastroenteritis outbreak;

(u) Giardiasis;

(v) Gonorrheal infection;

(w) Granuloma inguinale;

(x) Haemophilus influenzae invasive disease;

(y) Hansen's disease;

(z) Hantavirus pulmonary syndrome or infection;

(aa) Hemolytic uremic syndrome, post diarrheal;

(ab) Hepatitis A, acute;

(ac) Hepatitis B, acute, chronic, perinatal;

(ad) Hepatitis C, acute, infection, past or present;

(ae) Influenza;

(af) Lead poisoning (blood levels ≥ than 5 micrograms per deciliter for children 13 years of age or younger);

(ag) Legionellosis;

(ah) Listeriosis;

(ai) Lyme disease;

(aj) Lymphogranuloma venereum;

(ak) Malaria;

(al) Measles (rubeola);

(am) Meningococcal disease (Neisseria meningitidis);

(an) Mumps;

(ao) Pertussis;

(ap) Plague;

(aq) Poliomyelitis, paralytic or non-paralytic;

(ar) Psittacosis;

(as) Q-fever;

(at) Rabies in a human or animal; exposure to a human by a species susceptible to rabies infection;

(au) Rickettsiosis (spotted fever);

(av) Rubella (including congenital);

(aw) Salmonellosis;

(ax) Severe Acute Respiratory Syndrome-associated Coronavirus (SARS-CoV) disease;

(ay) Shigellosis;

(az) Smallpox;

(ba) Streptococcus pneumoniae, invasive disease;

(bb) Streptococcal toxic shock syndrome;

(bc) Syphilis;

(bd) Tetanus;

(be) Tickborne relapsing fever;

(bf) Toxic shock syndrome (nonstreptococcal);

(bg) Transmissible spongiform encephalopathies;

(bh) Trichinellosis (Trichinosis);

(bi) Tuberculosis;

(bj) Tularemia;

(bk) Typhoid fever;

(bl) Varicella;

(bm) Vibriosis;

(bn) Viral hemorrhagic fevers;

(bo) Yellow fever; and

(bp) Any unusual incident of unexplained illness or death in a human or animal with potential human health implications.

History: 50-1-202, 50-17-103, 50-18-105, 50-18-106, MCA; IMP, 50-1-202, 50-2-118, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1980 MAR p. 1579, Eff. 6/13/80; AMD, 1980 MAR p. 2870, Eff. 10/31/80; AMD, 1981 MAR p. 1289, Eff. 10/30/81; AMD, 1986 MAR p. 254, Eff. 2/28/86; AMD, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13.

Home  |   Search  |   About Us  |   Contact Us  |   Help  |   Disclaimer  |   Privacy & Security